Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719774 | 0.77 | MAPK13 (0.49) | NPBWR1KCNH2DGAT1 | |
| SCHEMBL16121162 | 0.74 | KDM4E (0.55) | PIK3CAPI4KBPIK3CDPIK3CBPI4KA | |
| SCHEMBL16102119 | 0.73 | NPC1 (0.62) | KCNH2HPGDDGAT1 | |
| SCHEMBL16121160 | 0.71 | KDM4E (0.45) | PIK3CAPI4KBPIK3CDPIK3CBPI4KA | |
| SCHEMBL28818932 | 0.71 | PIK3CA (0.41) | PIK3CAPI4KBPIK3CDPIK3CBPI4KA | |
| SCHEMBL1719292 | 0.70 | NPBWR1 (0.40) | NPBWR1KCNH2HPGDDGAT1 | |
| SCHEMBL16121405 | 0.70 | CHEK2 (0.47) | PIK3CAPI4KBPIK3CDPIK3CBPI4KA | |
| SCHEMBL16121404 | 0.70 | NPC1 (0.46) | PIK3CAPI4KBPIK3CDPIK3CBPI4KA | |
| SCHEMBL1720665 | 0.70 | TRPV1 (0.49) | KCNH2 | |
| SCHEMBL16121415 | 0.69 | TRPV1 (0.63) | NPBWR1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173735-B1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-01-11 | — | — | EP | disclosed |
| US-7935707-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090012063-A1 | Novel imidazole derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012063-A1 | Novel imidazole derivatives | CCR2, CCR1, CCR3 | PIK3CA 4222/4885PI4KB 3118/4885PIK3CD 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.